NovaSight announced that it is launching CureSight, its digital therapy for amblyopia, to the U.S. market this month.
The FDA granted CureSight 510(k) clearance in October, based on results of a randomized, controlled study that found the device to be noninferior to patching.
NovaSight also announced in a press release the appointment of Drew Hopper to vice president of sales and marketing North America. He will be instrumental in the launch of the technology.
“We are excited to bring CureSight into the U.S. market and to begin the process of (Read more...)